{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/VRAX",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Virax Biolabs Group Ltd (NASDAQ: VRAX) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Virax Biolabs Group Ltd, listed on NASDAQ under ticker VRAX. The ISIN is not on the record and the LEI is not on the record. The security type is Non-operating entity type (other). The segment is not on the record. The sector is 2835 In Vitro & In Vivo Diagnostic Substances. The jurisdiction is Cayman Islands. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 39 filings in the twelve months to 2026-11-08, across 33 filing days. The median gap between filing days is 8.0 days. The latest filing is dated 2026-10-29 and is of type results, 10 days before the record date. The NASDAQ median gap between filing days is 6.0 days, with a median of 52 filings and a median latency of 5.0 days. The sector median gap between filing days is 6.5 days, with a median of 61 filings and a median latency of 4 days.\n\n## Auditor\n\nThe auditor of record is not on the record, and the auditor's location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record. The segment move is not on the record. The issuer is listed and not halted.\n\n## Orderability\n\nThe outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nOne research house is named on the issuer's own investor-relations page: H.C. Wainwright & Co.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds the issuer's sealed years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://data.sec.gov/submissions/CIK0001885827.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/VRAX (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.viraxbiolabs.com/financial-information/analyst-coverage (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/VRAX (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/VRAX",
  "coverage": {
   "count": 1,
   "houses": [
    {
     "analyst": "Yi Chen, Ph.D. CFA",
     "house": "H.C. Wainwright & Co.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.viraxbiolabs.com/financial-information/analyst-coverage",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.viraxbiolabs.com/financial-information/analyst-coverage",
     "result": "read: 1 of 4 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 19,
     "median_cadence_gap_days": 6.5,
     "median_filings": 61,
     "median_latency_days": 4,
     "name": "2835 In Vitro & In Vivo Diagnostic Substances"
    }
   },
   "by_type": {
    "directors_dealings": 7,
    "prospectus": 6,
    "regulatory_filing": 6,
    "results": 20
   },
   "cadence_median_gap_days": 8,
   "filing_days": 33,
   "filings": 39,
   "latency_days": 10,
   "latest": [
    {
     "category": "6-K",
     "date": "2026-10-29",
     "source": "https://www.sec.gov/Archives/edgar/data/1885827/000119312526437018/6-k_10.29.26_china_distr.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "3",
     "date": "2026-10-21",
     "source": "https://www.sec.gov/Archives/edgar/data/1885827/000119312526427235/xslF345X06/ownership.xml",
     "title": "3 — 3",
     "type": "directors_dealings"
    },
    {
     "category": "6-K",
     "date": "2026-10-09",
     "source": "https://www.sec.gov/Archives/edgar/data/1885827/000119312526419117/6-k_coo_departure_oct_20.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "424B3",
     "date": "2026-09-10",
     "source": "https://www.sec.gov/Archives/edgar/data/1885827/000119312526386697/prospectus_sept_2026.htm",
     "title": "424B3 — 424B3",
     "type": "prospectus"
    },
    {
     "category": "6-K",
     "date": "2026-09-04",
     "source": "https://www.sec.gov/Archives/edgar/data/1885827/000119312526383683/6-k_atm_sticker_suppleme.htm",
     "title": "6-K — 6-K",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-10-29",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/VRAX",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "market": "US",
    "reason": "no LEI, so no GLEIF ISIN route; EDGAR carries no ISIN",
    "state": "not_on_record"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001885827.json",
    "state": "sourced",
    "value": "Cayman Islands"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-E9",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001885827.json",
    "state": "sourced",
    "value": "Virax Biolabs Group Ltd"
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001885827.json",
    "state": "sourced",
    "value": "2835 In Vitro & In Vivo Diagnostic Substances"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001885827.json",
    "state": "sourced",
    "value": "Non-operating entity type (other)"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "VRAX"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:37deb93c0a69cf2ceed72450d668b34a43ae7f184fd3e9cf5e3980d0040c9904",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/VRAX",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:37deb93c0a69cf2ceed72450d668b34a43ae7f184fd3e9cf5e3980d0040c9904",
 "path": "/us/NASDAQ/VRAX",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Virax Biolabs Group Ltd, listed on NASDAQ under ticker VRAX. The ISIN is not on the record and the LEI is not on the record. The security type is Non-operating entity type (other). The segment is not on the record. The sector is 2835 In Vitro & In Vivo Diagnostic Substances. The jurisdiction is Cayman Islands. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 39 filings in the twelve months to 2026-11-08, across 33 filing days. The median gap between filing days is 8.0 days. The latest filing is dated 2026-10-29 and is of type results, 10 days before the record date. The NASDAQ median gap between filing days is 6.0 days, with a median of 52 filings and a median latency of 5.0 days. The sector median gap between filing days is 6.5 days, with a median of 61 filings and a median latency of 4 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record, and the auditor's location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record. The segment move is not on the record. The issuer is listed and not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "One research house is named on the issuer's own investor-relations page: H.C. Wainwright & Co.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds the issuer's sealed years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001885827.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/VRAX"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.viraxbiolabs.com/financial-information/analyst-coverage"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/VRAX"
  }
 ],
 "title": "Virax Biolabs Group Ltd (VRAX) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}